Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Synta Pharmaceuticals, a US-based biopharmaceutical company, has named Dr Sumant Ramachandra as the new president of research and development (R&D).
Subscribe to our email newsletter
Dr Ramachandra served as senior vice president, R&D, regulatory and medical affairs, and chief scientific officer of Hospira.
Prior to Hospira, he served as vice president and oncology portfolio therapeutic area lead at Merck. He also served as therapeutic area head for medical oncology at Pfizer, prior to Merck/Schering-Plough.
Synta president and CEO Safi Bahcall said, "Sumant brings a broad range of development and regulatory leadership experience, as well as a unique perspective having led both oncology development at large pharmaceutical companies, and the broader range of R&D functions at a large, global specialty pharma company."
Synta possesses chemical compound library, an integrated discovery engine, and a variety of clinical- and preclinical-stage drug candidates.